Generic drug deal grants Czech Zentiva access to respiratory medicine market.

By bne IntelliNews October 4, 2010
Czech drug maker Zentiva, solely owned by French pharmaceuticals producer Sanofi-Aventis, bought the Inhaler Franchise project of global pharmaceuticals manufacturer Siegfried, in a deal to allow it to enter the market of respiratory medicines, the company said on its website. The acquisition will provide Zentiva with an attractive portfolio of assets that will allow it to become an important player in a market that is expected to develop rapidly after 2013, when generic respiratory products are forecast to be launched, the press release said. The Inhaler Franchise project includes a multi-dose dry powder inhaler as well as a range of new generic respiratory medicines to develop, Zentiva added. The transaction was structured as an acquisition of Siegfried's German subsidiary dedicated to the Inhaler Franchise project and an acquisition of related assets mainly including intellectual property. Both the company and the assets were legally acquired not by Zentiva, but by other companies within the Sanofi-Aventis group, the press release said. Sanofi-Aventis became the sole owner of local drugs maker Zentiva after completing the buyout of small shareholders on Mar 18 at the same price (CZK 1,150) it paid for purchasing majority (about 71%) stake at Zentiva.

Related Articles

Czech CSSD proposes 2014 general and European elections to be held together.

Social Democrats (CDDS), the major Czech opposition party, proposed next year's general and European elections to be held on the same day, CTK news agency reported. CSSD leader Bohuslav Sobotka ... more

Tesco Czech faces fine for selling products containing undeclared horsemeat

The Czech unit of UK retailer Tesco faces a fine of up to CZK 3mn (EUR 116,000) for selling beef lasagne containing undeclared horsemeat, Radio Prague reported. The state-run Agricultural and Food ... more

Czech Senate votes to limit immunity of lawmakers, judges.

The upper house of the Czech parliament, the Senate, voted on March 20 a constitutional amendment to limit the immunity of lawmakers and constitutional judges, Radio Prague reported. Out of the ... more

Register here to continue reading this article and 2 more for free or purchase 12 months full website access including the bne Magazine for just $119/year.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

Thank you. Please complete your registration by confirming your email address.
A confirmation email has been sent to the email address you provided.

To continue viewing our content you need to complete the registration process.

Please look for an email that was sent to with the subject line "Confirmation bne IntelliNews access". This email will have instructions on how to complete registration process. Please check in your "Junk" folder in case this communication was misdirected in your email system.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

If you have any questions please contact us at sales@intellinews.com

Subscribe to bne IntelliNews website and magazine

Subscribe to bne IntelliNews website and monthly magazine, the leading source of business, economic and financial news and commentary in emerging markets.

Your subscription includes:
  • Full access to the bne content daily news and features on the website
  • Newsletters direct to your mailbox
  • Print and digital subscription to the monthly bne magazine
  • Digital subscription to the weekly bne newspaper

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

bne IntelliNews
$119 per year

All prices are in US dollars net of applicable taxes.

If you have any questions please contact us at sales@intellinews.com

Register for free to read bne IntelliNews Magazine. You'll receive a free digital subscription.

Already a subscriber or registered - click here to recover access.

If you a IntelliNews Pro user - click here to login.

Thank you. Please complete your registration by confirming your email address.
A confirmation email has been sent to the email address you provided.

IntelliNews Pro offers daily news updates delivered to your inbox and in-depth data reports.
Get the emerging markets newswire that financial professionals trust.

"No day starts for my team without IntelliNews Pro" — UBS

Thank-you for requesting an IntelliNews Pro trial. Our team will be in contact with you shortly.

Dismiss